These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 30429022)
1. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022 [TBL] [Abstract][Full Text] [Related]
2. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy. Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843 [TBL] [Abstract][Full Text] [Related]
3. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930 [TBL] [Abstract][Full Text] [Related]
4. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204 [TBL] [Abstract][Full Text] [Related]
5. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710 [TBL] [Abstract][Full Text] [Related]
6. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747 [TBL] [Abstract][Full Text] [Related]
7. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020 [TBL] [Abstract][Full Text] [Related]
9. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551 [TBL] [Abstract][Full Text] [Related]
10. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review]. Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127 [No Abstract] [Full Text] [Related]
11. Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer. Sumi T; Sekikawa M; Koshino Y; Nagayama D; Nagahisa Y; Matsuura K; Shijubou N; Kamada K; Suzuki K; Ikeda T; Michimata H; Watanabe H; Yamada Y; Osuda K; Tanaka Y; Chiba H Thorac Cancer; 2024 Jul; 15(20):1572-1581. PubMed ID: 38828610 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747 [TBL] [Abstract][Full Text] [Related]
13. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy. Watanabe S; Ota T; Hayashi M; Ishikawa H; Otsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Miyabayashi T; Miura S; Tanaka H; Abe T; Okajima M; Terada M; Ishida T; Iwashima A; Sato K; Yoshizawa H; Kikuchi T Cancer Med; 2020 May; 9(9):3070-3077. PubMed ID: 32150668 [TBL] [Abstract][Full Text] [Related]
15. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270 [TBL] [Abstract][Full Text] [Related]
17. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439 [TBL] [Abstract][Full Text] [Related]
18. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871 [TBL] [Abstract][Full Text] [Related]
19. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Shibaki R; Murakami S; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Kusumoto M; Yamamoto N; Ohe Y Cancer Immunol Immunother; 2020 Jan; 69(1):15-22. PubMed ID: 31745589 [TBL] [Abstract][Full Text] [Related]
20. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]